Meanwhile, in NSD2-high multiple myeloma harboring t(4;14) translocation, all-trans retinoic acid (ATRA) induces the expression of CD38, in a dependent manner of NSD2-mediated H3K36me2, thus improving the efficacy of anti-CD38 CAR T-cell therapy [158]. The gene discussed is NSD2; the disease is plasma cell myeloma.